ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 372,94
-0,78%
Dow Jones
41 938,45
-1,63%
DAX
20 073,81
-0,73%
Brent Oil
80,555
-0,07%
Bitcoin
90 500,14
-4,22%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. IDEAYA Biosciences Inc (IDYA)

  7. IDEAYA Biosciences Inc (IDYA) Actualités

IDYA

IDEAYA Biosciences (IDYA)

IDEAYA Biosciences Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:IDYA
DateHeureSourceTitreSymboleSociété
12/01/202518h00PR Newswire (US)IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate GuidanceNASDAQ:IDYAIDEAYA Biosciences Inc
30/12/202412h04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IDYAIDEAYA Biosciences Inc
29/12/202412h00PR Newswire (US)IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid TumorsNASDAQ:IDYAIDEAYA Biosciences Inc
27/12/202412h00PR Newswire (US)IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:IDYAIDEAYA Biosciences Inc
20/12/202422h53Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IDYAIDEAYA Biosciences Inc
17/12/202412h00PR Newswire (US)IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal MelanomaNASDAQ:IDYAIDEAYA Biosciences Inc
16/12/202412h00PR Newswire (US)IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung CancersNASDAQ:IDYAIDEAYA Biosciences Inc
11/12/202412h00PR Newswire (US)IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024NASDAQ:IDYAIDEAYA Biosciences Inc
10/12/202412h00PR Newswire (US)IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial CancerNASDAQ:IDYAIDEAYA Biosciences Inc
09/12/202412h00PR Newswire (US)IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 InhibitorNASDAQ:IDYAIDEAYA Biosciences Inc
02/12/202412h00PR Newswire (US)IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations EventsNASDAQ:IDYAIDEAYA Biosciences Inc
18/11/202412h00PR Newswire (US)IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial OfficerNASDAQ:IDYAIDEAYA Biosciences Inc
12/11/202412h00PR Newswire (US)IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D DayNASDAQ:IDYAIDEAYA Biosciences Inc
11/11/202416h40Business WireBiocytogen kündigt die Nominierung des Entwicklungskandidaten IDE034 von IDEAYA, einem potenziellen ersten bispezifischen ADC (Antibody Drug Conjugate, Antikörper-Wirkstoff-Konjugat) der Klasse B7H3/PTK7 Topo-I-Nutzlast, sowie die Ausübung der...NASDAQ:IDYAIDEAYA Biosciences Inc
11/11/202416h40Business WireBiocytogen annonce la nomination par IDEAYA du candidat IDE034, un ADC bispécifique Topo-I-Payload B7H3/PTK7, ainsi que la levée d’une optionNASDAQ:IDYAIDEAYA Biosciences Inc
11/11/202412h00Business WireBiocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option ExerciseNASDAQ:IDYAIDEAYA Biosciences Inc
11/11/202412h00PR Newswire (US)IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with BiocytogenNASDAQ:IDYAIDEAYA Biosciences Inc
04/11/202414h30PR Newswire (US)/C O R R E C T I O N -- IDEAYA Biosciences, Inc./NASDAQ:IDYAIDEAYA Biosciences Inc
04/11/202412h00PR Newswire (US)IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:IDYAIDEAYA Biosciences Inc
28/10/202411h00PR Newswire (US)IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid TumorsNASDAQ:IDYAIDEAYA Biosciences Inc
25/10/202412h00PR Newswire (US)IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024NASDAQ:IDYAIDEAYA Biosciences Inc
04/10/202412h00PR Newswire (US)IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR SymposiumNASDAQ:IDYAIDEAYA Biosciences Inc
27/09/202422h25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IDYAIDEAYA Biosciences Inc
23/09/202412h00PR Newswire (US)IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal MelanomaNASDAQ:IDYAIDEAYA Biosciences Inc
22/09/202415h00PR Newswire (US)IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024NASDAQ:IDYAIDEAYA Biosciences Inc
18/09/202412h00PR Newswire (US)IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General CounselNASDAQ:IDYAIDEAYA Biosciences Inc
26/08/202423h16Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:IDYAIDEAYA Biosciences Inc
26/08/202412h00PR Newswire (US)IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceNASDAQ:IDYAIDEAYA Biosciences Inc
06/08/202423h08Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:IDYAIDEAYA Biosciences Inc
06/08/202422h13Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IDYAIDEAYA Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:IDYA

Dernières Valeurs Consultées

NASDAQ
GOOGL
Alphabet
EU
RI
Pernod Ricard
EU
CS
Axa
COIN
AVAXUSD
Avalanche
COIN
BTCUSD
Bitcoin
NASDAQ
AMZN
Amazon.com
NASDAQ
MSFT
Microsoft
EU
PX4
SBF 120
NYSE
MRK
Merck
COIN
XRPUSD
Ripple
NYSE
JPM
JP Morgan Chase
EU
AI
Air Liquide
EU
VK
Vallourec
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés